San Diego, CA — August 14, 2018 – Synthetic Genomics, Inc. (SGI), a leader in designing and programming biology for function, today announced J. Craig Venter, Ph.D., has retired from his longtime position as Chairman of the company’s Board of Directors to focus on his work at the J. Craig Venter Institute (JCVI). Dr. Venter will remain a Scientific Advisor to SGI.
SAN DIEGO, CA. July 2, 2018 — SGI-DNA, a leader in commercial DNA synthesis, today announced industry veteran Todd R. Nelson, Ph.D., MBA has been appointed Chief Executive Officer to lead the spin-out of the company from Synthetic Genomics, Inc. (SGI).
SAN DIEGO, CA — June 25, 2018 — Synthetic Genomics, Inc. (SGI), a leader in designing and programming biology for function, today announced Reinhard J. Ambros, Ph.D., has joined the company’s Board of Directors.
SAN DIEGO, May 11, 2018 – Synthetic Genomics, Inc. announced today that Oliver Fetzer, Ph.D., MBA, Chief Executive Officer, will present at the upcoming Bank of America Merrill Lynch 2018 Healthcare Conference and the Jefferies 2018 Global Healthcare Conference.
Irving, TX & La Jolla, CA – March 6, 2018 – ExxonMobil and Synthetic Genomics Inc. today announced a new phase in their joint algae biofuel research program that could lead to the technical ability to produce 10,000 barrels of algae biofuel per day by 2025.
Los Angeles & La Jolla, CA – February 28, 2018 – C3J Therapeutics, Inc., a private biotechnology company focused on the development of novel targeted antimicrobials, and Synthetic Genomics, Inc., (SGI) a leader in designing and programming biology for desired function, announced today an agreement between the two companies to integrate SGI’s proprietary engineered bacteriophage (or phage) platform with C3J’s R&D programs addressing high unmet medical needs linked to infectious diseases.
San Diego, CA – October 31, 2017 – Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. The collaboration will bring together Arcturus’s LUNAR™ lipid-mediated delivery platform with Synthetic Genomics’ RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics.
San Diego, CA – October 31, 2017 – Synthetic Genomics, Inc. announced today that the company has entered into a collaboration with Ceva Santé Animale to utilize Synthetic Genomics’ next-generation synthetic RNA replicon platform to develop vaccines for livestock. The technology opens the door to more effective vaccines and therapeutics.
San Diego, CA — October 26, 2017 — Synthetic Genomics, Inc. is part of the recently funded DARPA Pandemic Prevention Platform (P3) program aimed at establishing a system capable of halting viral pandemics within 60 days. As part of the collaboration, led by Duke, Synthetic Genomics will contribute synthetic biology technologies to enable rapid delivery of anti-viral countermeasures.
Flanders, Belgium & San Diego, CA – Aug. 22, 2017 – SGI-DNA Inc., a Synthetic Genomics Inc. (SGI) company, and VIB, a Belgian life science research institute, today announced that VIB will become the first institute in Europe to integrate the BioXp™ 3200 System in its workflows as part of its vision for adopting breakthrough technologies. The BioXp™ 3200 System is the world’s first benchtop automated genomic workstation that rapidly prints high-quality, double-stranded DNA fragments and clones into any vector in an overnight run. With the BioXp™ 3200 System, VIB will be accelerating turnaround time for generating custom DNA for genomic research.